Basma Abdulhadi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Basma Abdulhadi has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Andrea Gillis
Department of Surgery, University of Alabama at Birmingham, Birmingham, AL 35233, USA
1 shared publication Azeem Izhar
Department of Surgery, University of Alabama at Birmingham , Birmingham, AL 35233, USA
1 shared publicationBrenessa Lindeman
Department of Surgery, University of Alabama at Birmingham , Birmingham, AL 35233, USA
1 shared publication- Daniel Gomez-Carrillo
University of Alabama at Birmingham
1 shared publication Hameeda Arif Arain
Department of Surgery, University of Alabama at Birmingham , Birmingham, AL 35233, USA
1 shared publication- Herbert Chen
Department of Surgery, University of Alabama at Birmingham, Birmingham, AL 35233, USA
1 shared publication
Latest Publications
- 3 August 2026
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 111 (12) , e2552-e2564
Change in bone mineral density after parathyroidectomy for secondary hyperparathyroidism: a review
Context: Secondary hyperparathyroidism is a common complication of chronic kidney disease that accelerates bone loss and increases fracture risk. While parathyroidectomy (PTx) is the definitive treatment for medically refractory cases, its impact on bone mineral density (BMD) has not been comprehensively evaluated. Evidence Acquisition: A systematic search of PubMed, Embase, and Scopus was conducted from inception through January 2026. Studies were included if they reported dual-energy X-ray absorptiometry-measured BMD before and after PTx in adults with secondary hyperparathyroidism due to chronic kidney disease. Two reviewers independently screened and selected studies using the Population, Intervention, Comparison, Outcomes, Study Design framework, and additional articles were identified through reference searching. Evidence Synthesis: Across 11 studies encompassing 452 patients with paired measurements, all demonstrated significant improvement in BMD following a site-specific hierarchy favoring cancellous bone. The lumbar spine (+7-50% g/cm2) and femoral neck (+8-23% g/cm2) showed the most consistent gains, while the distal radius showed minimal change. Higher preoperative parathyroid hormone levels, elevated alkaline phosphatase, and lower baseline BMD were associated with greater skeletal recovery. The only available randomized trial confirmed the superiority of PTx over cinacalcet for bone density improvement. Conclusion: PTx consistently improves BMD in patients with refractory secondary hyperparathyroidism, with the greatest gains at cancellous-rich skeletal sites. Clinicians should consider the skeletal benefits of PTx when counseling patients with medically refractory disease, particularly those with low baseline bone density and markedly elevated parathyroid hormone levels.
- 3 August 2026
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 111 (12) , e2552-e2564
Change in bone mineral density after parathyroidectomy for secondary hyperparathyroidism: a review
Context: Secondary hyperparathyroidism is a common complication of chronic kidney disease that accelerates bone loss and increases fracture risk. While parathyroidectomy (PTx) is the definitive treatment for medically refractory cases, its impact on bone mineral density (BMD) has not been comprehensively evaluated. Evidence Acquisition: A systematic search of PubMed, Embase, and Scopus was conducted from inception through January 2026. Studies were included if they reported dual-energy X-ray absorptiometry-measured BMD before and after PTx in adults with secondary hyperparathyroidism due to chronic kidney disease. Two reviewers independently screened and selected studies using the Population, Intervention, Comparison, Outcomes, Study Design framework, and additional articles were identified through reference searching. Evidence Synthesis: Across 11 studies encompassing 452 patients with paired measurements, all demonstrated significant improvement in BMD following a site-specific hierarchy favoring cancellous bone. The lumbar spine (+7-50% g/cm2) and femoral neck (+8-23% g/cm2) showed the most consistent gains, while the distal radius showed minimal change. Higher preoperative parathyroid hormone levels, elevated alkaline phosphatase, and lower baseline BMD were associated with greater skeletal recovery. The only available randomized trial confirmed the superiority of PTx over cinacalcet for bone density improvement. Conclusion: PTx consistently improves BMD in patients with refractory secondary hyperparathyroidism, with the greatest gains at cancellous-rich skeletal sites. Clinicians should consider the skeletal benefits of PTx when counseling patients with medically refractory disease, particularly those with low baseline bone density and markedly elevated parathyroid hormone levels.